Navigation Links
Codexis Appoints Interim Chief Executive Officer
Date:2/17/2012

REDWOOD CITY, Calif., Feb. 17, 2012 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a developer of industrial enzymes to enable the production of biofuels, bio-based chemicals, and pharmaceutical intermediates, today announced that effective immediately, the Board of Directors has appointed Peter Strumph as the company's interim Chief Executive Officer.  Alan Shaw, Ph.D. has resigned as President and Chief Executive Officer and from the Board of Directors to pursue other interests.  He will continue to serve as a special advisor to the Board of Directors.  The Board of Directors has appointed a special committee that will oversee the CEO search and transition.  Heidrick & Struggles has been retained for a worldwide search, which will include both internal and external candidates.

"We are grateful to Alan for his many years of service in leading Codexis from its inception and are pleased that he has agreed to serve as a special advisor to the Board," said Thomas Baruch, Chairman of the Board for Codexis, Inc.  "We are confident that Peter's executive leadership experience and deep understanding of the business will ensure a smooth transition during our search for a permanent CEO."

"Codexis has a tremendous leadership team in place, and I am pleased to continue supporting the company as it works to commercialize industrial enzymes in the biofuel, chemical and pharmaceutical industries," said Dr. Shaw.

Mr. Strumph was the Senior Vice President and Business Head of Pharmaceuticals, where he oversaw a 49% annual increase in pharmaceutical product sales in 2011, as well as the Senior Vice President of Commercial Operations since joining Codexis in 2010.  Mr. Strumph has more than twenty years experience in senior manufacturing and operations management in the biopharmaceutical industry, including executive leadership positions for ten years at CV Therapeutics where he managed their operational, development and commercial activities.  He is a former Naval officer, and holds an MBA from the University of Pennsylvania's Wharton School of Business.   

About Codexis, Inc.

Codexis, Inc. is a developer of industrial enzymes to enable the production of biofuels, bio-based chemicals and pharmaceutical intermediates.  Codexis' product lines include CodeXyme™ Cellulase Enzymes and CodeXol™ Detergent Alcohol.  Partners and customers include global leaders such as Shell, Merck and Pfizer.  For more information, see www.codexis.com.

 

Contacts:
Investors: Jay Sarwar, ir@codexis.com, 650-421-8126
Media: Wes Bolsen, media@codexis.com, 650-421-8100


'/>"/>
SOURCE Codexis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Codexis Announces CFO Departure
2. Codexis to Announce Fourth Quarter and Fiscal Year 2011 Financial Results on February 7, 2012
3. Codexis Reports Third Quarter 2011 Results
4. 50 Pharma Companies Worldwide Now Use Codexis In Process Development
5. Codexis Names Veteran Chemical Executive to Lead Codexis do Brasil
6. Codexis, Raizen to Develop First Generation Ethanol
7. Codexis to Present at Three Investor Conferences in September
8. Codexis Presents Carbon Capture Update at DoE/NETL Conference
9. Codexis Board Elects Pedro I. Mizutani, Raizen EVP, as Director
10. Codexis Reports Second Quarter 2011 Results
11. Codexis and Chemtex to Collaborate on Sustainable Detergent Alcohols for the Household Products Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017  Zimmer Biomet Holdings, Inc. ... healthcare, today announced that it will be participating in ... at the InterContinental Hotel in Boston, Massachusetts ... will present at 11:20 a.m. Eastern Time. ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
(Date:4/20/2017)... WOONSOCKET, R.I. , April 20, 2017 /PRNewswire/ ... (NYSE: CVS), today unveiled a new store design ... new assortment of healthier food, health-focused products and ... the store to help customers discover new offerings. ... represent the next evolution of the customer experience ...
(Date:4/20/2017)... Eyevensys, a private biotechnology company developing its ... that enables the safe, local, sustained production of therapeutic ... of ophthalmic diseases, announces it has received approval from ... to advance its technology into clinical development. ... The EyeCET platform uses ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... 2017 , ... ProRehab Physical Therapy (PRPT) is ... therapy provider for Derby City CrossFit, effective immediately. , In addition to treating ... effectively as possible, ProRehab’s sports physical therapists will work with athletes to maximize ...
(Date:4/25/2017)... BC (PRWEB) , ... April 25, 2017 , ... The ... from Richmond, BC, who live with dental fear and require sedation to receive dental ... at ease during various procedures, from hygienic cleanings to oral surgery, at their ...
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers ... back pain with a reputable physician in their area, announces the launch of a ... information for patients who are looking for reputable physicians to help them with back ...
(Date:4/25/2017)... ... 25, 2017 , ... There is no better place in South Florida to ... in the May issue of Consumer Reports focused on heart health. , The ... during and after coronary bypass and aortic valve replacement procedures. , Consumer Reports ...
(Date:4/24/2017)... ... 24, 2017 , ... Michael Vick announced his retirement earlier this year from ... overall number one pick in the 2001 NFL Draft, to the Atlanta Falcons, made ... the most career rushing yards by a quarterback (6,109) and the most rushing yards ...
Breaking Medicine News(10 mins):